Nicox Extraordinary General Meeting of July11, 2022
Sophia Antipolis,
Dear valued Shareholder,
This letter is sent to ask for your continued valuable support for
I would like to start by introducing myself. My name is Andreas Segerros and I have succeeded
Ophthalmology in general and glaucoma in particular is part of my business DNA. I spent 12 years with Pharmacia Ophthalmics and had the opportunity to lead the development and global launch of Xalatan® (latanoprost), which became Pharmacia’s first
With this in-depth knowledge of the ophthalmology market, and its demands, I have joined
During 2021 the Company strengthened its R&D leadership with the recruitment of Doug Hubatsch as Chief Scientific Officer. He also has a deep ophthalmology background from Alcon and Novartis and has developed and launched several glaucoma products in his career. This closes the loop on having a strong company leadership team that can handle the work relating both to post-Phase 3 activities and simultaneously continuing to build a targeted and clinically relevant pipeline in ophthalmology.
As we look back, 2021 has been a year where the full strength of the Company has been deployed, most notably in the execution of the two NCX 470 Phase 3 trials. The Phase 3 program consists of two pivotal trials,
Strong support from
Your support and your vote at the upcoming Extraordinary General Meeting are very important to us being able to continue to build the company and its capabilities.
For this purpose, a proxy form, the resolutions, a guide explaining how to vote, and several other documents pertaining to the Extraordinary General Meeting are enclosed. All the documents pertaining to the General Meeting are available on Nicox’s website www.nicox.com (section Investors/Shareholder Meetings).
Should you have any question on the voting process, please contact our Investor Relations team either by e-mail at age2022nicox@nicox.com or by phone at +33 (0)4 97 24 53 28.
Yours sincerely,
Andreas Segerros
Chief Executive Officer
Attachment
- AGE 2022_EN_F
© OMX, source